BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maleszewski JJ, Younge BR, Fritzlen JT, Hunder GG, Goronzy JJ, Warrington KJ, Weyand CM. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol 2017;30:788-96. [PMID: 28256573 DOI: 10.1038/modpathol.2017.10] [Cited by in Crossref: 78] [Cited by in F6Publishing: 93] [Article Influence: 15.6] [Reference Citation Analysis]
Number Citing Articles
1 Parreau S, Liozon E, Chen JJ, Curumthaullee MF, Fauchais AL, Warrington K, Ly KH, Weyand CM. TEMPORAL ARTERY BIOPSY: A TECHNICAL GUIDE AND REVIEW OF ITS IMPORTANCE & INDICATIONS. Surv Ophthalmol 2022:S0039-6257(22)00120-5. [PMID: 35995251 DOI: 10.1016/j.survophthal.2022.08.008] [Reference Citation Analysis]
2 Watanabe R, Hashimoto M. Pathogenic role of monocytes/macrophages in large vessel vasculitis. Front Immunol 2022;13:859502. [DOI: 10.3389/fimmu.2022.859502] [Reference Citation Analysis]
3 Marvisi C, Muratore F, Cabassi C, Galli E, Boiardi L, Piana S, Mengoli MC, Salvarani C, Cavazza A. What to Know About Biopsy Sampling and Pathology in Vasculitis? Curr Rheumatol Rep 2022. [PMID: 35895226 DOI: 10.1007/s11926-022-01082-6] [Reference Citation Analysis]
4 Kermani TA, Warrington KJ, Dua AB. Treatment Guidelines in Vasculitis. Rheumatic Disease Clinics of North America 2022. [DOI: 10.1016/j.rdc.2022.03.006] [Reference Citation Analysis]
5 Muniz Castro HM, Bhattacharjee MB, Chaudhry IA, Chuang AZ, Mankiewicz KA, Adesina OO. Diagnosis of Giant Cell Arteritis using Clinical, Laboratory, and Histopathological Findings in Patients Undergoing Temporal Artery Biopsy. Clinical Neurology and Neurosurgery 2022. [DOI: 10.1016/j.clineuro.2022.107377] [Reference Citation Analysis]
6 Watanabe R, Hashimoto M. Vasculitogenic T Cells in Large Vessel Vasculitis. Front Immunol 2022;13:923582. [DOI: 10.3389/fimmu.2022.923582] [Reference Citation Analysis]
7 van der Geest KSM, Sandovici M, Nienhuis PH, Slart RHJA, Heeringa P, Brouwer E, Jiemy WF. Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica. Front Med 2022;9:902155. [DOI: 10.3389/fmed.2022.902155] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Héron E, Sedira N, Dahia O, Jamart C. Ocular Complications of Giant Cell Arteritis: An Acute Therapeutic Emergency. JCM 2022;11:1997. [DOI: 10.3390/jcm11071997] [Reference Citation Analysis]
9 Sandovici M, van der Geest N, van Sleen Y, Brouwer E. Need and value of targeted immunosuppressive therapy in giant cell arteritis. RMD Open 2022;8:e001652. [PMID: 35149602 DOI: 10.1136/rmdopen-2021-001652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Vieira M, Régnier P, Maciejewski-Duval A, Le Joncour A, Darasse-Jèze G, Rosenzwajg M, Klatzmann D, Cacoub P, Saadoun D. Interferon signature in giant cell arteritis aortitis. J Autoimmun 2022;127:102796. [PMID: 35123212 DOI: 10.1016/j.jaut.2022.102796] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
11 Samson M, Bonnotte B. Comment appliquer les recommandations EULAR et ACR pour le diagnostic et le traitement de l’artérite à cellules géantes ? La Revue de Médecine Interne 2022. [DOI: 10.1016/j.revmed.2022.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kuret T, Frank-bertoncelj M, Lakota K, Žigon P, Thallinger GG, Kopitar AN, Čučnik S, Tomšič M, Hočevar A, Sodin-šemrl S. From Active to Non-active Giant Cell Arteritis: Longitudinal Monitoring of Patients on Glucocorticoid Therapy in Combination With Leflunomide. Front Med 2022;8:827095. [DOI: 10.3389/fmed.2021.827095] [Reference Citation Analysis]
13 Bolha L, Hočevar A, Suljič A, Jurčić V. Inflammatory Cell Composition and Immune-Related microRNA Signature of Temporal Artery Biopsies From Patients With Giant Cell Arteritis. Front Immunol 2021;12:791099. [PMID: 35003111 DOI: 10.3389/fimmu.2021.791099] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Pugh D, Karabayas M, Basu N, Cid MC, Goel R, Goodyear CS, Grayson PC, McAdoo SP, Mason JC, Owen C, Weyand CM, Youngstein T, Dhaun N. Large-vessel vasculitis. Nat Rev Dis Primers 2022;7:93. [PMID: 34992251 DOI: 10.1038/s41572-021-00327-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
15 Biros E, Malabu UH, Vangaveti VN, Birosova E, Moran CS. The IFN-γ-mini/TrpRS signaling axis: an insight into the pathophysiology of osteoporosis and therapeutic potential. Cytokine & Growth Factor Reviews 2022. [DOI: 10.1016/j.cytogfr.2022.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Tomelleri A, van der Geest KSM, Sebastian A, van Sleen Y, Schmidt WA, Dejaco C, Dasgupta B. Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage. The Lancet Rheumatology 2021;3:e886-95. [DOI: 10.1016/s2665-9913(21)00277-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ciccia F, Macaluso F, Mauro D, Nicoletti GF, Croci S, Salvarani C. New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine? The Lancet Rheumatology 2021;3:e874-85. [DOI: 10.1016/s2665-9913(21)00253-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Micieli JA, Grossniklaus HE, Peragallo JH. Masquerades of Giant Cell Arteritis Evident on Temporal Artery Biopsy. J Clin Rheumatol 2021;27:e568-74. [PMID: 31124922 DOI: 10.1097/RHU.0000000000001072] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Solimando AG, Vacca A, Dammacco F. Highlights in clinical medicine-Giant cell arteritis, polymyalgia rheumatica and Takayasu's arteritis: pathogenic links and therapeutic implications. Clin Exp Med 2021. [PMID: 34741677 DOI: 10.1007/s10238-021-00770-4] [Reference Citation Analysis]
20 Esen I, Jiemy WF, van Sleen Y, van der Geest KSM, Sandovici M, Heeringa P, Boots AMH, Brouwer E. Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment. J Clin Med 2021;10:4958. [PMID: 34768479 DOI: 10.3390/jcm10214958] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
21 Alnaimat F, Mansour AT, Alduraidi H, Al-Qasem S, Hindi M, Rawashdeh T, Hassan E, Almustafa S, Hanbali R, Ababneh O. Clinical and technical determinants of positive temporal artery biopsy: a retrospective cohort study. Rheumatol Int 2021;41:2157-66. [PMID: 34661710 DOI: 10.1007/s00296-021-05028-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Oshinsky C, Bays AM, Sacksen I, Jernberg E, Zierler RE, Diamantopoulos AP, Liew JW, Chung SH, Pollock PS. Vascular Ultrasound for Giant Cell Arteritis: Establishing a Protocol Using Vascular Sonographers in a Fast-Track Clinic in the United States. ACR Open Rheumatol 2021. [PMID: 34647696 DOI: 10.1002/acr2.11346] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Galetta K, Bhattacharyya S. Acute Neurologic Manifestations of Systemic Immune-Mediated Diseases. Semin Neurol 2021;41:541-53. [PMID: 34619780 DOI: 10.1055/s-0041-1733790] [Reference Citation Analysis]
24 Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol 2021;73:1349-65. [PMID: 34235884 DOI: 10.1002/art.41774] [Cited by in Crossref: 2] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
25 Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care Res (Hoboken) 2021;73:1071-87. [PMID: 34235871 DOI: 10.1002/acr.24632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
26 Garvey TD, Koster MJ, Warrington KJ. My Treatment Approach to Giant Cell Arteritis. Mayo Clin Proc 2021;96:1530-45. [PMID: 34088416 DOI: 10.1016/j.mayocp.2021.02.013] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Walters B, Lazic D, Ahmed A, Yiin G. Lessons of the month 4: Giant cell arteritis with normal inflammatory markers and isolated oculomotor nerve palsy. Clin Med (Lond) 2020;20:224-6. [PMID: 32188666 DOI: 10.7861/clinmed.2019-0504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Cohen DA, Chen JJ, Neth BJ, Sabbagh N, Hodge D, Warrington KJ, Fillmore J, Maleszewski JJ, Salomao DR, Bhatti MT. Discordance Rate Among Bilateral Simultaneous and Sequential Temporal Artery Biopsies in Giant Cell Arteritis: Role of Frozen Sectioning Based on the Mayo Clinic Experience. JAMA Ophthalmol 2021;139:406-13. [PMID: 33599705 DOI: 10.1001/jamaophthalmol.2020.6896] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Bursi R, Cafaro G, Perricone C, Riccucci I, Calvacchi S, Gerli R, Bartoloni E. Contribution of Janus-Kinase/Signal Transduction Activator of Transcription Pathway in the Pathogenesis of Vasculitis: A Possible Treatment Target in the Upcoming Future. Front Pharmacol 2021;12:635663. [PMID: 33854436 DOI: 10.3389/fphar.2021.635663] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
30 Bosch P, Dejaco C, Schmidt WA, Schlüter KD, Pregartner G, Schäfer VS. Ultrasound for diagnosis and follow-up of chronic axillary vasculitis in patients with long-standing giant cell arteritis. Ther Adv Musculoskelet Dis 2021;13:1759720X21998505. [PMID: 33796156 DOI: 10.1177/1759720X21998505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Parreau S, Vedrenne N, Regent A, Richard L, Sindou P, Mouthon L, Fauchais AL, Jauberteau MO, Ly KH. An immunohistochemical analysis of fibroblasts in giant cell arteritis. Ann Diagn Pathol 2021;52:151728. [PMID: 33798926 DOI: 10.1016/j.anndiagpath.2021.151728] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
32 Robinette ML, Rao DA, Monach PA. The Immunopathology of Giant Cell Arteritis Across Disease Spectra. Front Immunol 2021;12:623716. [PMID: 33717128 DOI: 10.3389/fimmu.2021.623716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
33 Akiyama M, Ohtsuki S, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Innate and Adaptive Immunity in Giant Cell Arteritis. Front Immunol 2020;11:621098. [PMID: 33717054 DOI: 10.3389/fimmu.2020.621098] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
34 Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, Czihal M, Dechant C, Dejaco C, Garske U, Henes J, Holle JU, Holl-Ulrich K, Lamprecht P, Nölle B, Moosig F, Rech J, Scheuermann K, Schmalzing M, Schmidt WA, Schneider M, Schulze-Koops H, Venhoff N, Villiger PM, Witte T, Zänker M, Hellmich B. [S2k guidelines: management of large-vessel vasculitis]. Z Rheumatol 2020;79:67-95. [PMID: 33156399 DOI: 10.1007/s00393-020-00893-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
35 Serling-Boyd N, Stone JH. Recent advances in the diagnosis and management of giant cell arteritis. Curr Opin Rheumatol 2020;32:201-7. [PMID: 32168069 DOI: 10.1097/BOR.0000000000000700] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
36 Harrington R, Al Nokhatha SA, Conway R. Biologic Therapies for Giant Cell Arteritis. Biologics 2021;15:17-29. [PMID: 33442231 DOI: 10.2147/BTT.S229662] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
37 Emamifar A, Ellingsen T, Hess S, Gerke O, Hviid Larsen R, Ahangarani Farahani Z, Syrak Hansen P, Jensen Hansen IM, Petersen H, Marcussen N, Dahlstrøm M, Toftegaard P, Thye-Rønn P. The Utility of 18F-FDG PET/CT in Patients With Clinical Suspicion of Polymyalgia Rheumatica and Giant Cell Arteritis: A Prospective, Observational, and Cross-sectional Study. ACR Open Rheumatol 2020;2:478-90. [PMID: 33439554 DOI: 10.1002/acr2.11163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Griffin DK, Irvine DA, Chakrabarty DA, Mackie DS. The relevance of restricted inflammation in a TAB. Semin Arthritis Rheum 2021:S0049-0172(21)00003-2. [PMID: 33589237 DOI: 10.1016/j.semarthrit.2021.01.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Galli E, Muratore F, Boiardi L, Cavazza A, Salvarani C. Response to 'The Relevance of Restricted Inflammation in a TAB' by Griffin KJ et al. Semin Arthritis Rheum 2021:S0049-0172(21)00004-4. [PMID: 33451760 DOI: 10.1016/j.semarthrit.2021.01.004] [Reference Citation Analysis]
40 van der Geest KSM, Wolfe K, Borg F, Sebastian A, Kayani A, Tomelleri A, Gondo P, Schmidt WA, Luqmani R, Dasgupta B. Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. Rheumatology (Oxford) 2020:keaa806. [PMID: 33355340 DOI: 10.1093/rheumatology/keaa806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
41 Mackie SL, Brouwer E, Conway R, van der Geest KSM, Mehta P, Mollan SP, Neill L, Putman M, Robinson PC, Sattui SE. Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. Lancet Rheumatol 2021;3:e71-82. [PMID: 33521671 DOI: 10.1016/S2665-9913(20)30386-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
42 Wang L, Ai Z, Khoyratty T, Zec K, Eames HL, van Grinsven E, Hudak A, Morris S, Ahern D, Monaco C, Eruslanov EB, Luqmani R, Udalova IA. ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies. JCI Insight 2020;5:139163. [PMID: 32960815 DOI: 10.1172/jci.insight.139163] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
43 Deshayes S, de Boysson H, Dumont A, Vivien D, Manrique A, Aouba A. An overview of the perspectives on experimental models and new therapeutic targets in giant cell arteritis. Autoimmunity Reviews 2020;19:102636. [DOI: 10.1016/j.autrev.2020.102636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Liozon E, Dumonteil S, Parreau S, Gondran G, Bezanahary H, Palat S, Ly KH, Fauchais AL. Risk profiling for a refractory course of giant cell arteritis: The importance of age and body weight: "Risk profiling for GC resistance in GCA". Semin Arthritis Rheum 2020;50:1252-61. [PMID: 33065420 DOI: 10.1016/j.semarthrit.2020.09.009] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Cellular Signaling Pathways in Medium and Large Vessel Vasculitis. Front Immunol 2020;11:587089. [PMID: 33072134 DOI: 10.3389/fimmu.2020.587089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
46 Sené T, Arej N, Lecler A, Dupont C, Vasseur V, Mauget-Faÿsse M, Vignal-Clermont C. Visual Recovery with Iloprost Added to Corticosteroids in a Case of Giant Cell Arteritis. Ocul Immunol Inflamm 2020;:1-3. [PMID: 32976035 DOI: 10.1080/09273948.2020.1802489] [Reference Citation Analysis]
47 Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis-Similarities and Differences. Curr Rheumatol Rep 2020;22:68. [PMID: 32845392 DOI: 10.1007/s11926-020-00948-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
48 Mackie SL, Brouwer E. What can negative temporal artery biopsies tell us? Rheumatology (Oxford) 2020;59:925-7. [PMID: 31995202 DOI: 10.1093/rheumatology/kez628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
49 Camellino D, Matteson EL, Buttgereit F, Dejaco C. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. Nat Rev Rheumatol 2020;16:481-95. [DOI: 10.1038/s41584-020-0458-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
50 Sené T, Clavel G, Villeneuve D, Philibert M, Mauget-Faÿsse M, Lamirel C, Lecler A, Gout O, Hage R, Lidove O, Vignal-Clermont C. [Delays in the management of ocular complications of giant cell arteritis: A retrospective monocentric study of 33 patients]. Rev Med Interne 2020;41:661-6. [PMID: 32682624 DOI: 10.1016/j.revmed.2020.06.012] [Reference Citation Analysis]
51 Stamatis P. Giant Cell Arteritis versus Takayasu Arteritis: An Update. Mediterr J Rheumatol 2020;31:174-82. [PMID: 32676554 DOI: 10.31138/mjr.31.2.174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
52 Chung SH, Morcos MB, Ng B. Determinants of Positive Temporal Artery Biopsies in the Veterans Health Administration National Database Cohort. Arthritis Care Res (Hoboken) 2020;72:699-704. [PMID: 30932359 DOI: 10.1002/acr.23897] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
53 Unizony S, Kermani TA. IL-6 Blockade and its Therapeutic Success in Giant Cell Arteritis. J Neuroophthalmol 2018;38:551-8. [PMID: 30199509 DOI: 10.1097/WNO.0000000000000713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 Régnier P, Le Joncour A, Maciejewski-Duval A, Desbois AC, Comarmond C, Rosenzwajg M, Klatzmann D, Cacoub P, Saadoun D. Targeting JAK/STAT pathway in Takayasu's arteritis. Ann Rheum Dis 2020;79:951-9. [PMID: 32213496 DOI: 10.1136/annrheumdis-2019-216900] [Cited by in Crossref: 18] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
55 Sammel AM, Hsiao E, Schembri G, Bailey E, Nguyen K, Brewer J, Schrieber L, Janssen B, Youssef P, Fraser CL, Laurent R. Cranial and large vessel activity on positron emission tomography scan at diagnosis and 6 months in giant cell arteritis. Int J Rheum Dis 2020;23:582-8. [PMID: 32100451 DOI: 10.1111/1756-185X.13805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
56 Zhang H, Watanabe R, Berry GJ, Nadler SG, Goronzy JJ, Weyand CM. CD28 Signaling Controls Metabolic Fitness of Pathogenic T Cells in Medium and Large Vessel Vasculitis. J Am Coll Cardiol 2019;73:1811-23. [PMID: 30975299 DOI: 10.1016/j.jacc.2019.01.049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
57 Chew BJW, Khajuria A, Ibanez J. The Impact of Temporal Artery Biopsy at a UK Tertiary Plastic Surgery Unit. Plast Reconstr Surg Glob Open 2019;7:e2541. [PMID: 31942316 DOI: 10.1097/GOX.0000000000002541] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
58 Watanabe R, Maeda T, Zhang H, Berry GJ, Zeisbrich M, Brockett R, Greenstein AE, Tian L, Goronzy JJ, Weyand CM. MMP (Matrix Metalloprotease)-9-Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis. Circ Res 2018;123:700-15. [PMID: 29970365 DOI: 10.1161/CIRCRESAHA.118.313206] [Cited by in Crossref: 38] [Cited by in F6Publishing: 58] [Article Influence: 12.7] [Reference Citation Analysis]
59 Mcdonald HM, Farmer JP, Blanco PL. Periadventitial tissue examination in temporal artery biopsies for suspected giant cell arteritis: a case series and literature review. Canadian Journal of Ophthalmology 2019;54:615-20. [DOI: 10.1016/j.jcjo.2018.12.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
60 Sailler L, Paricaud K. [Giant cell arteritis: Ischemic complications]. Presse Med 2019;48:948-55. [PMID: 31564551 DOI: 10.1016/j.lpm.2019.09.013] [Reference Citation Analysis]
61 Samson M, Bonnotte B. [New concepts in giant cell arteritis]. Presse Med 2019;48:917-8. [PMID: 31564552 DOI: 10.1016/j.lpm.2019.09.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
62 Régent A, Ly KH, Mouthon L. [Physiopathology of giant cell arteritis: From inflammation to vascular remodeling]. Presse Med 2019;48:919-30. [PMID: 31543394 DOI: 10.1016/j.lpm.2019.07.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
63 Monti S, Águeda AF, Luqmani RA, Buttgereit F, Cid M, Dejaco C, Mahr A, Ponte C, Salvarani C, Schmidt W, Hellmich B. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open 2019;5:e001003. [PMID: 31673411 DOI: 10.1136/rmdopen-2019-001003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
64 Moragas Solanes M, Andreu Magarolas M, Martín Miramon J, Caresia Aróztegui A, Monteagudo Jiménez M, Oliva Morera J, Diaz Martín C, Rodríguez Revuelto A, Bravo Ferrer Z, Bernà Roqueta L. Comparative study of 18F-FDG PET/CT and CT angiography in the detection of large vessel vasculitis. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2019;38:280-9. [DOI: 10.1016/j.remnie.2019.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Neß T, Schmidt W. [Eye involvement in large vesssel vasculitis (giant cell arteritis and Takayasu's arteritis)]. Ophthalmologe 2019;116:899-914. [PMID: 31463637 DOI: 10.1007/s00347-019-00959-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
66 van Sleen Y, Graver JC, Abdulahad WH, van der Geest KSM, Boots AMH, Sandovici M, Brouwer E. Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica. Front Immunol 2019;10:1981. [PMID: 31507597 DOI: 10.3389/fimmu.2019.01981] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
67 Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, Cassie R, Cid MC, Dasgupta B, Dejaco C, Hatemi G, Hollinger N, Mahr A, Mollan SP, Mukhtyar C, Ponte C, Salvarani C, Sivakumar R, Tian X, Tomasson G, Turesson C, Schmidt W, Villiger PM, Watts R, Young C, Luqmani RA. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020;79:19-30. [PMID: 31270110 DOI: 10.1136/annrheumdis-2019-215672] [Cited by in Crossref: 192] [Cited by in F6Publishing: 263] [Article Influence: 64.0] [Reference Citation Analysis]
68 Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony SH, Collinson N. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis Rheumatol 2019;71:1329-38. [PMID: 30835950 DOI: 10.1002/art.40876] [Cited by in Crossref: 33] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
69 Moragas Solanes M, Andreu Magarolas M, Martín Miramon JC, Caresia Aróztegui AP, Monteagudo Jiménez M, Oliva Morera JC, Diaz Martín C, Rodríguez Revuelto A, Bravo Ferrer Z, Bernà Roqueta LL. Comparative study of 18F-FDG PET/CT and CT angiography in detection of large vessel vasculitis. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2019;38:280-9. [PMID: 31126839 DOI: 10.1016/j.remn.2019.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Berlit P, Krämer M; Consensus Group. Cerebral involvement in systemic vasculitides: Extracts from the guideline of the German neurological society. Neurol Res Pract 2019;1:13. [PMID: 33324879 DOI: 10.1186/s42466-019-0016-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
71 Banerjee S, Quinn KA, Gribbons KB, Rosenblum JS, Civelek AC, Novakovich E, Merkel PA, Ahlman MA, Grayson PC. Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis. J Rheumatol 2020;47:99-107. [PMID: 30877209 DOI: 10.3899/jrheum.181222] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
72 van Sleen Y, Sandovici M, Abdulahad WH, Bijzet J, van der Geest KSM, Boots AMH, Brouwer E. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology (Oxford) 2019:kez034. [PMID: 30805622 DOI: 10.1093/rheumatology/kez034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
73 Weyand CM, Watanabe R, Zhang H, Akiyama M, Berry GJ, Goronzy JJ. Cytokines, growth factors and proteases in medium and large vessel vasculitis. Clin Immunol 2019;206:33-41. [PMID: 30772599 DOI: 10.1016/j.clim.2019.02.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
74 Low C, Conway R. Current advances in the treatment of giant cell arteritis: the role of biologics. Ther Adv Musculoskelet Dis 2019;11:1759720X19827222. [PMID: 30800174 DOI: 10.1177/1759720X19827222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
75 Graver JC, Boots AMH, Haacke EA, Diepstra A, Brouwer E, Sandovici M. Massive B-Cell Infiltration and Organization Into Artery Tertiary Lymphoid Organs in the Aorta of Large Vessel Giant Cell Arteritis. Front Immunol 2019;10:83. [PMID: 30761147 DOI: 10.3389/fimmu.2019.00083] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
76 Croci S, Bonacini M, Muratore F, Caruso A, Fontana A, Boiardi L, Soriano A, Cavazza A, Cimino L, Belloni L, Perry O, Fridkin M, Parmeggiani M, Blank M, Shoenfeld Y, Salvarani C. The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. J Autoimmun 2019;98:113-21. [PMID: 30638709 DOI: 10.1016/j.jaut.2019.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
77 Aschwanden M, Schegk E, Imfeld S, Staub D, Rottenburger C, Berger CT, Daikeler T. Vessel wall plasticity in large vessel giant cell arteritis: an ultrasound follow-up study. Rheumatology 2019;58:792-7. [DOI: 10.1093/rheumatology/key383] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
78 Conway R, O'neill L, Gallagher P, Mccarthy GM, Murphy CC, Veale DJ, Fearon U, Molloy ES. Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial. Seminars in Arthritis and Rheumatism 2018;48:523-8. [DOI: 10.1016/j.semarthrit.2018.04.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 9.5] [Reference Citation Analysis]
79 Lee SW, Kim SJ, Seo Y, Jeong SY, Ahn BC, Lee J. F-18 FDG PET for assessment of disease activity of large vessel vasculitis: A systematic review and meta-analysis. J Nucl Cardiol 2019;26:59-67. [PMID: 30120746 DOI: 10.1007/s12350-018-1406-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
80 Banz Y, Stone JH. Why do temporal arteries go wrong? Principles and pearls from a clinician and a pathologist. Rheumatology (Oxford) 2018;57:ii3-ii10. [PMID: 29982782 DOI: 10.1093/rheumatology/kex524] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
81 Schmidt WA. Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology (Oxford) 2018;57:ii22-31. [PMID: 29982780 DOI: 10.1093/rheumatology/kex461] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 19.0] [Reference Citation Analysis]
82 Schäfer VS, Chrysidis S, Dejaco C, Duftner C, Iagnocco A, Bruyn GA, Carrara G, D’agostino MA, De Miguel E, Diamantopoulos AP, Fredberg U, Hartung W, Hocevar A, Juche A, Kermani TA, Koster MJ, Lorenzen T, Macchioni P, Milchert M, Døhn UM, Mukhtyar C, Ponte C, Ramiro S, Scirè CA, Terslev L, Warrington KJ, Dasgupta B, Schmidt WA. Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. J Rheumatol 2018;45:1289-95. [DOI: 10.3899/jrheum.171428] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
83 Jiemy WF, Heeringa P, Kamps JA, van der Laken CJ, Slart RH, Brouwer E. Positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging of macrophages in large vessel vasculitis: Current status and future prospects. Autoimmunity Reviews 2018;17:715-26. [DOI: 10.1016/j.autrev.2018.02.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
84 Markose G, Graham RM. Re: re: Gillies temporal incision: an alternative approach to biopsy of the superficial temporal artery. Br J Oral Maxillofac Surg 2018;56:434-5. [PMID: 29716748 DOI: 10.1016/j.bjoms.2018.03.013] [Reference Citation Analysis]
85 Slart RHJA; Writing group., Reviewer group., Members of EANM Cardiovascular., Members of EANM Infection & Inflammation., Members of Committees, SNMMI Cardiovascular., Members of Council, PET Interest Group., Members of ASNC., EANM Committee Coordinator. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging 2018;45:1250-69. [PMID: 29637252 DOI: 10.1007/s00259-018-3973-8] [Cited by in Crossref: 142] [Cited by in F6Publishing: 147] [Article Influence: 35.5] [Reference Citation Analysis]
86 Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, Malayeri AA, Merkel PA, Novakovich E, Bluemke DA, Ahlman MA. 18 F-Fluorodeoxyglucose-Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis. Arthritis Rheumatol 2018;70:439-49. [PMID: 29145713 DOI: 10.1002/art.40379] [Cited by in Crossref: 129] [Cited by in F6Publishing: 130] [Article Influence: 32.3] [Reference Citation Analysis]
87 Wenter V, Sommer NN, Kooijman H, Maurus S, Treitl M, Czihal M, Dechant C, Unterrainer M, Albert NL, Treitl KM. Clinical value of [18F]FDG-PET/CT and 3D-black-blood 3T-MRI for the diagnosis of large vessel vasculitis and single-organ vasculitis of the aorta. Q J Nucl Med Mol Imaging 2020;64:194-202. [PMID: 29307167 DOI: 10.23736/S1824-4785.18.03036-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
88 Weyand CM, Berry GJ, Goronzy JJ. The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease. J Leukoc Biol 2018;103:565-75. [PMID: 28848042 DOI: 10.1189/jlb.3MA0717-283] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
89 Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis. Circulation 2018;137:1934-48. [PMID: 29254929 DOI: 10.1161/CIRCULATIONAHA.117.030423] [Cited by in Crossref: 73] [Cited by in F6Publishing: 95] [Article Influence: 14.6] [Reference Citation Analysis]
90 Koster MJ, Warrington KJ. Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets. BMC Rheumatol 2017;1:2. [PMID: 30886946 DOI: 10.1186/s41927-017-0004-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
91 Koster MJ, Warrington KJ. Vasculitis syndromes: Tocilizumab - a new frontier for GCA therapy. Nat Rev Rheumatol 2017;13:700-1. [PMID: 28878334 DOI: 10.1038/nrrheum.2017.150] [Reference Citation Analysis]
92 Cinar I, Wang H, Stone JR. Clinically isolated aortitis: pitfalls, progress, and possibilities. Cardiovasc Pathol 2017;29:23-32. [PMID: 28500877 DOI: 10.1016/j.carpath.2017.04.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
93 Watanabe R, Zhang H, Berry G, Goronzy JJ, Weyand CM. Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol 2017;312:H1052-9. [PMID: 28314758 DOI: 10.1152/ajpheart.00024.2017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 57] [Article Influence: 9.6] [Reference Citation Analysis]